Publication date: Jan 08, 2025
Long COVID (LC) is a complex multisymptom condition with no known disease-modifying treatments. This wait-list-controlled open-label trial tested whether a remotely delivered structured weight management program could improve respective LC symptoms in people living with overweight. Adults with LC (symptoms >12 weeks) and body mass index >27 kg m (>25 kg m for South Asians) were randomized (n = 234, 1:1) to control (n = 116, usual care) or the remotely delivered structured weight management (n = 118, total diet replacement (850 kcal per day) for 12 weeks, followed by food reintroduction and weight loss maintenance support) via minimization and randomization (80:20) to balance dominant LC symptom, sex, age, ethnicity and postcode-based index of multiple deprivation between groups. The control group received the intervention after 6 months. Participants selected the dominant LC symptom they would most like to improve (fatigue, breathlessness, pain, anxiety/depression or other) as the prespecified respective primary outcome. Individual symptoms were assessed using validated questionnaires and a visual analog scale for those without prespecified scales. At 6 months, the primary outcome improved in the intervention group (change -1. 16 (s. d. 1. 42), n = 97 analyzed) compared with the control group (change -0. 83 (s. d. 1. 14), n = 117 analyzed) with a treatment effect of -0. 34 (95% confidence interval -0. 67 to -0. 01), with no excess of serious adverse events. International Standard Randomised Controlled Trial Number Registry registration: ISRCTN 12595520 .
Open Access PDF
| Concepts | Keywords |
|---|---|
| 12weeks | Control |
| 850kcal | Controlled |
| Asians | Covid |
| Diet | Delivered |
| Disease | Group |
| List | |
| Long | |
| Management | |
| Overweight | |
| Randomized | |
| Structured | |
| Symptoms | |
| Trial | |
| Wait | |
| Weight |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | long COVID |
| disease | MESH | overweight |
| disease | MESH | weight loss |
| drug | DRUGBANK | Isoxaflutole |
| disease | IDO | symptom |
| disease | IDO | intervention |
| disease | MESH | breathlessness |
| disease | MESH | anxiety |
| disease | MESH | depression |
| disease | MESH | COVID 19 |
| disease | IDO | disposition |
| disease | MESH | weight gain |
| disease | MESH | infection |
| disease | MESH | etiology |
| disease | MESH | cardiovascular diseases |
| drug | DRUGBANK | Spinosad |
| disease | MESH | inflammation |
| disease | MESH | obesity |
| disease | IDO | blood |
| drug | DRUGBANK | Imidacloprid |
| disease | MESH | Hypertension |
| disease | MESH | diabetes mellitus |
| drug | DRUGBANK | Trestolone |